Studies indicate that immunosuppressed populations, including HIV/AIDS patients, cancer patients, transplant recipients, and those on haemodialysis, are at higher risk for flu infection. Vaccination has shown promise in reducing flu cases, but more research is needed to assess vaccine efficacy and timing for optimal protection.
Researchers from Brown University and Harvard School of Public Health found that Brazil's efforts to treat people living with HIV/AIDS using generic medicines saved the country over $1 billion. The study also showed that the country was able to contain the virus, minimize its spread, and provide treatment to over 660,000 Brazilians.
A study found that improper use and fit of walkers and canes result in 47,000 emergency room visits annually. Physical therapists recommend assessing and fitting walking aids to prevent injuries.
A team of Canadian and American researchers have identified a way to treat HIV-AIDS by targeting both viruses in the body and those hiding in immune system cells. This breakthrough opens the door for innovative therapies that differ from current approaches.
The Einstein Proteomics Research Center aims to identify brain proteins responsible for neurological complications in people infected with HIV, particularly those who are also addicted to drugs. The center will investigate the mechanism of HIV infection and develop biomarkers to detect neurological disease.
Top HIV/AIDS researchers at NIAID outline a test-and-treat strategy that could reduce HIV incidence by 90% within 10 years. The proposal also involves pre-exposure prophylaxis, latent virus control, and improved prevention strategies.
A new study published in Clinical Nursing Research found that marijuana use is common among HIV/AIDS patients in the US to alleviate symptoms such as anxiety, depression, and nausea. The study suggests that therapeutic marijuana use merits further consideration among policy makers, despite potential risks associated with its use.
A new Stanford University study finds that early antiretroviral treatment can reduce the risk of death or complications in HIV-positive patients with serious AIDS-related conditions. The treatment was shown to improve immune system function and increase survival rates by 50 percent.
The Center for Proteomics and Bioinformatics at Case Western Reserve will expand its activities in HIV/AIDS research with a $989,108 grant from NIDA. The grant aims to develop reliable biomarkers for chronic immune activation during HIV disease and explore the effects of current or prior drug use on disease progression.
The Multicenter AIDS Cohort Study (MACS) has significantly contributed to the scientific understanding of HIV/AIDS through its 25 years of behavioral and biological data. Key findings include identifying unique features of long-term non-progressors, managing HIV treatment, and the link between viral load and progression of HIV disease.
The UCSF Visiting Professor Program has provided training and mentoring to 40 visiting professors from minority universities, resulting in over $50 million in research funding and 425 scientific publications. The program accelerates careers and promotes interdisciplinary approaches to HIV/AIDS prevention research.
The University of Pittsburgh has received a five-year, $2.8 million grant to develop training sites in Mozambique, Brazil, and India for HIV/AIDS researchers. The program aims to equip local researchers with skills to monitor patients and combat drug resistance.
A study published in The Lancet found that early antiretroviral treatment can significantly improve survival rates among HIV-positive patients. By initiating treatment when CD4 cell counts fall between 351 and 450 cells/µL, the risk of AIDS development and death was reduced by 28%.
A new study analyzing over 45,000 people with HIV in Europe and North America found that starting combination antiretroviral therapy (cART) at a minimum CD4-cell count of 350 cells per µL reduces AIDS-related events and death rates. The findings challenge current guidelines recommending cART initiation at a lower threshold.
A Stanford study found that the US AIDS Relief program reduced HIV/AIDS death tolls by over 10% in targeted African countries, saving an estimated 1 million lives. However, there was no significant impact on disease prevalence rates.
African Americans are disproportionately affected by AIDS, yet few are pursuing HIV/AIDS research due to historical, social, and other factors. Recommendations from UCLA researchers aim to reverse the trend by supporting partnerships, retraining, mentorship, and culturally congruent research.
A new paper by academics from Scotland and the US explores Brazil's role in changing global AIDS policy and promoting widespread access to AIDS treatment. Brazil's successful HIV/AIDS treatment program is considered a model for other developing countries.
Increased schooling across sub-Saharan Africa may lower new HIV infections among younger adults, contradicting previous views of education as an AIDS risk factor. Formal education appears to reduce the risk of HIV infections by up to 34 percent in some countries.
Researchers at the University of Gothenburg have developed a new method to describe and quantify relationships between dose, concentration, and effectiveness of drugs against HIV/AIDS and malaria. The study found that genetic differences can influence efavirenz metabolism and that reducing daily doses can minimize undesired effects.
Leading scientists issue a challenge to find a way to purge latent HIV infection and eliminate the need for chronic therapy. A drug-free remission goal requires understanding of persistent infection reservoirs and combination approaches.
The International Association of Physicians in AIDS Care has submitted recommendations to the Obama administration, emphasizing the need for a proactive approach to strengthen US HIV/AIDS programs and global health initiatives. The organization advocates for scaling up HIV prevention activities in developing countries and promoting evi...
The CANTAM network, the first EDCTP-funded regional Network of Excellence, aims to build research capacity in Central Africa. Partner institutions from Cameroon, Congo, Gabon, Tanzania, and Germany will collaborate to conduct clinical trials under best practices.
A study found a 13% incidence of major depression disorder and a 21% incidence of other depressive disorders among HIV/AIDS patients in Kenya. The Patient Health Questionnaire-9 (PHQ-9) screening tool was shown to be reliable and valid for assessing severity and diagnosis in this population.
A comprehensive survey of global spending on neglected disease R&D found that just over $2.5 billion was invested in 2007, with HIV/AIDS, TB, and malaria receiving nearly 80% of the total funding. Many neglected diseases are underfunded, with some receiving less than 4% of global funding.
The Ragon Institute aims to unlock the mysteries of the immune system to find new ways of preventing and curing human disease. Its initial focus will be on identifying effective immune responses in HIV-infected individuals and designing strategies to induce those responses.
The team aims to enhance access and retention in quality HIV care for women of color by developing a web-based data entry and reporting platform. Recent HIV data highlights significant disparities among black and Hispanic women, who account for 82% of AIDS diagnoses despite making up only 24% of all US women.
The Lancet emphasizes the importance of a competitive merit-based selection process for the new PEPFAR head. Key qualifications include visionary leadership, global health expertise, and experience in collaboration with various stakeholders.
Martin Delaney, founder of Project Inform, received the NIAID Director's Special Recognition Award for his efforts on behalf of HIV-infected people. He played a key role in expanding access to life-saving antiretroviral medications.
A variant of the protein Nef has been identified as a potential target for HIV treatment, with the goal of suppressing its production to prevent AIDS progression. Researchers believe that a drug affecting Nef could provide protection against the virus and complement existing therapies.
A study of 1833 HIV patients found that specific mitochondrial DNA genotypes accelerate AIDS development, while others delay it. This suggests that genetic tests could provide accurate prognoses and guide early treatment initiation.
UC Davis researchers are exploring a new gene therapy approach to cure AIDS by replacing HIV-infected immune cells with HIV-resistant ones. They plan to conduct safety and efficacy trials using a mouse model before moving on to human clinical trials.
The African AIDS Vaccine Programme (AAVP) is a network of African HIV vaccine stakeholders working towards an AIDS-free continent. The programme, established in 2000, supports and represents diverse communities involved in HIV vaccine research and development.
Despite progress, 33 million people live with HIV, and 2.7 million new infections occur each year. New treatments and prevention strategies are underway to combat the disease.
A meta-analysis published by the American Association for Cancer Research found that individuals with HIV have a higher risk of non-AIDS cancers compared to the general population. The risk is significantly higher for men than women, and incidence rates are similar between those with AIDS and without.
A study led by Beth Israel Deaconess Medical Center demonstrates a T-cell-based HIV-1 vaccine strategy may be effective in fighting AIDS. The vaccine regimen induced potent immune responses, reducing viral replication and preventing AIDS development in monkeys.
The study estimates that more than 330,000 lives were lost to HIV/AIDS in South Africa between 2000 and 2005 due to the delay in implementing antiretroviral treatment. The researchers also found that an estimated 35,000 babies were born with HIV during this period due to the lack of a mother-to-child transmission prophylaxis program.
Researchers found strong associations between markers of inflammation and coagulation and increased risk of death from non-AIDS diseases. Biomarkers IL-6 and D-dimer levels were unchanged in patients receiving continuous ART treatment, suggesting a link to intermittent ART.
A study published in the journal AIDS found that HIV-infected patients taking efavirenz had higher treatment adherence and lower rates of virologic failure and death compared to those taking nevirapine. This suggests a more favorable clinical outcome for efavirenz-based therapies.
A recent study found that African-American blogs provide a unique platform for discussing HIV and AIDS, allowing individuals to express themselves freely and anonymously. The researchers identified three key risk factors for the Black community: ineffective leadership, Black cultural practices, and individual behaviors.
According to a new analysis, NTDs as a group may have surpassed HIV/AIDS, tuberculosis, and malaria as the most prevalent infectious diseases in Latin America and the Caribbean. The region is home to approximately 200 million people affected by NTDs, including intestinal worm infections and Chagas disease.
A team of scientists found that sooty mangabeys have less immune system activation during SIV infection, explaining why they don't develop AIDS. This difference may hold key to understanding the mechanisms underlying AIDS progression in humans.
A novel approach to treating HIV/AIDS uses customized dendritic cells to stimulate immune response, showing potential for innovative therapeutic approach
Researchers from Michigan State University found that many low-cost over-the-counter hearing aids fail to meet basic fitting requirements and may damage a person's hearing. The study advises consumers to consult with an audiologist for proper fitting and customization.
A new study funded by the Economic and Social Research Council argues that hope is essential for effective HIV prevention strategies. People with hope are more likely to adopt realistic plans and engage in protective behaviors.
Robert Siliciano, an HIV expert, says that current antiretroviral drug combinations can suppress the ability of HIV to replicate, with some combos reducing copies to less than one in a billion. However, progress is still needed to identify and eliminate viral reservoirs that persist in the body.
The Lancet series highlights the importance of combination prevention approaches, combining behavioural, medical, and structural strategies. The authors warn that global prevention efforts are woefully insufficient, with fewer than 10% of individuals at risk receiving key services.
A study published in the journal AIDS has found that long-term antiretroviral therapy for HIV may offer protection against atherosclerosis. The Multicenter AIDS Cohort Study measured coronary artery calcification in nearly 950 HIV-positive and HIV-negative men, finding CAC scores were almost 60% lower in those on HAART.
A study found that a rectal tenofovir gel can prevent the transmission of an AIDS-like virus in macaques. The gel was applied before exposure and protected most animals from infection. However, more research is needed to confirm its effectiveness in humans.
The International AIDS Society–USA Panel updated treatment guidelines to reflect recent data on antiretroviral therapy. The new guidelines recommend starting therapy before CD4 cell count declines to less than 350/μL, with individualized regimens tailored to patient needs.
A study of 3,116 patients with and without a history of injection drug use found similar survival rates after 4-5 years of receiving HAART. The results challenge the prevailing notion that IDUs may not derive full benefits from HAART due to social instability.
A special supplement in the AIDS journal offers concrete recommendations for addressing social and economic issues fueling HIV, including building a diverse group of leaders and integrating treatment programs. The edition outlines actionable goals and calls for accountability to combat the epidemic more efficiently.
The Journal of Allergy and Clinical Immunology has published a special issue focusing on AIDS and HIV research, featuring reviews on vaccine development, B-cell abnormalities, and viral reservoirs. Key findings also include an increased rate of asthma in HIV-infected children treated with HAART.
Researchers will explore how HIV infection causes immune activation and depletion, with potential for clinical applications in AIDS treatment. The grant supports four projects ranging from basic lab research to experimental models and translational research.
The HIV/AIDS epidemic affects nearly 2 million people in Latin America and the Caribbean, with most transmission through unprotected sex. The region faces unique challenges due to socio-economic disparities, homophobia, and lack of access to healthcare and education.
A recent study published in PLoS Neglected Tropical Diseases found that parasitic worm infections can increase the risk of acquiring HIV/AIDS. The study showed that rhesus macaques with acute schistosomiasis were more susceptible to an HIV-like virus, with higher peak viral loads and memory cell concentrations.
A study by Dr. Nicole Bernard of McGill University Health Centre found that specific genes KIR3DL1 and HLA-B*57 provide innate resistance to HIV infection. People carrying these gene versions may be able to destroy infected cells more efficiently, lowering their risk of developing AIDS.
A new hearing aid technology has been shown to improve speech intelligibility in noisy environments like restaurants. The open-fit hearing aids with directional microphones outperformed traditional options and provided a 20% improvement in speech clarity.
A new study led by NYU Dentistry shows that weak HIV viruses can replicate and contribute to AIDS development through cooperative interaction with stronger viruses. This mechanism enables some viruses to reproduce faster and evade immune responses.
Researchers at the University of Pennsylvania School of Medicine have successfully modified T cell receptors using zinc fingers to develop a new type of AIDS treatment. The approach involves introducing mutations into the CCR5 gene, rendering it non-functional and preventing HIV entry into immune system cells.
Access to antiretroviral therapy has been associated with substantial reductions in HIV incidence. Expanded access can reduce AIDS-related illness and deaths, making it a viable prevention strategy.